PRIORITY PARTNERS
7231 Parkway Dr., Suite 100
Hanover, MD 21076

JOHNS HOPKINS
HEALTH PLANS

Prior Authorization

JOHNS HOPKINS HEALTH PLANS (MEDICAID)

Tetrabenazine - Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at **1-410-424-4607**. Please contact Johns Hopkins Health Plans at **1-888-819-1043** with questions regarding the Prior Authorization process.
When conditions are met, we will authorize the coverage of Tetrabenazine - Priority Partners MCO.

Drug Name (select from list of drugs shown)
Tetrabenazine

Quantity Frequency Strength

Route of Administration Expected Length of Therapy

Patient Information
Patient Name: _____
Patient ID: _____
Patient Group No.: _____
Patient DOB: _____
Patient Phone:

Prescribing Physician
Physician Name: _____
Physician Phone: _____
Physician Fax: _____
Physician Address: _____
City, State, Zip: _____

Diagnosis: _____ **ICD Code:** _____

Comments: _____

Please circle the appropriate answer for each question.

1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)? Y N

NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.

[If yes, skip to question 5.]

2. Does the patient have a diagnosis of chorea associated with Huntington's disease? Y N

	NOTE: Documentation must be submitted.	
	[If no, no further questions.]	
3.	Is the prescribed dose 100 milligrams per day or less?	Y N
	[If no, no further questions.]	
4.	Does the patient have any of the following exclusions to therapy: A) concomitant use of tetrabenazine and Austedo, B) Patient has suicidal or has suicidal ideations, C) Patient has untreated or inadequately treated depression, D) Patient has impaired hepatic function, E) Patient is currently using a monoamine oxidase inhibitor, F) Patient is currently using reserpine or has used reserpine in the past 20 days, G) Patient is pediatric?	Y N
	[No further questions.]	
5.	Is there clinical documentation supporting continued benefit of the requested medication?	Y N
	NOTE: Documentation must be submitted.	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date